Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2014. The report details a specific corporate action regarding share repurchases executed on May 8, 2014, following shareholder authorization at the Annual General Meeting held on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 508,543 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,630.50 pence per share; lowest price paid was 1,610.50 pence per share.
- Treasury Holdings (Settled): 489,174,669 shares, representing 9.14% of total issued share capital.
- Treasury Holdings (Including Unsettled): 490,513,712 shares, representing 10.09% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,861,116,487 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 508,543 shares on May 8, 2014. Consequently, the percentage of shares held in Treasury increased to 10.09% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, future outlook, management commentary on operations, or discussion of risks and contingencies. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (490,513,712) against the company's latest capitalization table.
- Confirm the 10.09% voting rights threshold held in Treasury for disclosure rule calculations.
- Check the settlement status of the 508,543 shares purchased on May 8, 2014.
- Review the Annual General Meeting minutes from May 7, 2014, to confirm the scope of the share repurchase authority.